Skip to main
MNMD
MNMD logo

MNMD Stock Forecast & Price Target

MNMD Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Mind Medicine Inc. is advancing toward significant clinical milestones with its lead asset, MM120, which is in Phase 3 studies targeting Generalized Anxiety Disorder (GAD) and has shown strong efficacy in earlier trials. The upcoming readouts from these studies are scheduled for the first half of 2026 and the second half of 2026, indicating a timely progression in the company's developmental timeline. Additionally, the initiation of commercial initiatives and robust engagement with payers highlights the company's proactive approach to market readiness, potentially enhancing its prospects for revenue generation as products progress through clinical development.

Bears say

Mind Medicine Inc. faces significant financial risks due to potential challenges surrounding its patent protections, which could hinder its market success and lead to a decrease in valuation. Furthermore, the company's late-stage clinical developments are susceptible to regulatory approval risks, as failure to secure necessary approvals could adversely affect both Mind Medicine and its collaborators. These factors contribute to a cautious outlook on the company's future financial performance and market viability.

MNMD has been analyzed by 6 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Mind Medicine MindMed and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Mind Medicine MindMed (MNMD) Forecast

Analysts have given MNMD a Buy based on their latest research and market trends.

According to 6 analysts, MNMD has a Buy consensus rating as of Oct 17, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $27.83, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $27.83, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Mind Medicine MindMed (MNMD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.